Abstract:After oral administration to rats, compared with amorphous cyclosporine A (CsA) powder, CsA‐loaded mucopenetrating nanoparticles increased bioavailability by 43‐fold and shortened the time to maximum plasma concentration (Tmax), while CsA‐loaded mucoadhesive nanoparticles prolonged Tmax. This study aimed to control the oral absorption of cyclosporine A (CsA) with the use of a mucosal drug delivery system (mDDS). Mucopenetrating nanocarriers (MP/NCs) and mucoadhesive nanocarriers (MA/NCs) were prepared by flash nanoprecipitation employing polystyrene‐block‐poly(ethylene glycol) and polystyrene‐block‐poly(N,N‐dimethyl aminoethyl methacrylate), respectively. Their particle distribution in the rat gastrointestinal tract were visualized by fluorescent imaging. Plasma concentrations were monitored after oral administration of CsA‐loaded MP/NCs (MP/CsA) and MA/NCs (MA/CsA) to rats. MP/NCs and MA/NCs had a particle size below 200 nm and ζ‐potentials of 4 and 40 mV, respectively. The results from in vitro experiments demonstrated mucopenetration of MP/NCs and mucoadhesion of MA/NCs. Confocal laser scanning microscopic images showed diffusion of MP/NCs in the gastrointestinal mucus towards epithelial cells and localization of MA/NCs on the surface of the gastrointestinal mucus layer. In a pH 6.8 solution, rapid and sustained release of CsA were observed for MP/CsA and MA/CsA, respectively. After oral dosing (10 mg‐CsA/kg) to rats, amorphous CsA powder exhibited a time to maximum plasma concentration (Tmax) of 3.4 h, maximum plasma concentration (Cmax) of 0.12 μg/mL, and bioavailability of 0.7%. Compared with amorphous CsA powder, MP/CsA shortened Tmax by 1.1 to 2.3 h and increased the bioavailability by 43‐fold to 30.1%, while MA/CsA prolonged Tmax by 3.4 to 6.8 h with Cmax and bioavailability of 0.65 μg/mL and 11.7%, respectively. These pharmacokinetic behaviors would be explained by their diffusion and release properties modulated by polymeric surface modification. The mDDS approach is a promising strategy for the pharmacokinetic control of orally administered CsA.

The Effect of Particle Size on the Absorption of Cyclosporin A Nanosuspension Through the Gastrointestinal Barrier

The Effect of Particle Size on the Absorption of Cyclosporin A Nanosuspensions

Enhancement of Oral Bioavailability of Cyclosporine A: Comparison of Various Nanoscale Drug-Delivery Systems.

Solid Self-Nanoemulsifying Cyclosporine A Pellets Prepared by Fluid-Bed Coating: Stability and Bioavailability Study

Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles

[Preparation of Cyclosporine A Ph Sensitive Nanoparticles and Oral Pharmacokinetics in Rats].

Studies on Mechanism to Promote Intestinal Absorption of Cyclosporine A & Formulation Factors

Preparation, Physicochemical Properties and Oral Bioavailability in Rats of Cyclosporine A-loaded Amphiphilic Chitosan Micelles

Everted Gut Sac as a Technique to Study the Absorption Behavior of Cyclosporin A Nanoliposome

Highly Drug-Loaded Nanoaggregate Microparticles for Pulmonary Delivery of Cyclosporin A

Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation.

Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

Preparation and in Vitro Characterizations of Cyclosporine A Ocular Nanostructured Lipid Carriers

Effect of Surface Modification on the Uptake of Polylactic Acid Nanoparticles Loading Cyclosporine A by Cells in Vitro and on the Body Distribution in Vivo

Ph-Sensitive Nanoparticles for Improving the Oral Bioavailability of Cyclosporine A.

Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system

Effect of Particle Size on in Vitro and in Vivo Behavior of Astilbin Nanosuspensions

Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat.

Pharmacokinetics and Enhanced Oral Bioavailability in Beagle Dogs of Cyclosporine A Encapsulated in Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles

Particle size effect of curcumin nanosuspensions on cytotoxicity, cellular internalization, in vivo pharmacokinetics and biodistribution

Pharmacokinetics and Biodistribution of Cyclosporine A Nanoparticles in Mice